Difference between revisions of "Belumosudil (Rezurock)"
Jump to navigation
Jump to search
(new FDA approval) |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2021-07-16: Approved for adult and pediatric patients 12 years and older with chronic [[Graft versus host disease|graft-versus-host disease]] (chronic GVHD) after failure of at least two prior lines of systemic therapy. ''(Based on KD025-213)'' |
==Also known as== | ==Also known as== | ||
Revision as of 14:02, 7 May 2023
Mechanism of action
ROCK2 (Rho-associated coiled-coil kinase 2) inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2021-07-16: Approved for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. (Based on KD025-213)
Also known as
- Code names: KD025, SLx-2119
- Brand name: Rezurock